Integra Lifesciences Holdings Corporation · NASDAQ:IART
Integra Lifesciences — 2023 JP Morgan Healthcare Conference
20 slides from Integra Lifesciences's conference presentation, Jan 10, 2023
Slide 1: 2023 JP Morgan Healthcare Conference
2023 JP Morgan Healthcare Conference January 11, 2023 Exhibit 99.2
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure 2 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other tha
Slide 3: Integra at a Glance
Integra at a Glance Restoring patients lives through breakthrough technologies in neuro and regenerative care 3 Transformative leader in Neuro -access, -surgery, -monitoring Leading provider of specialty instruments solutions Codman Specialty Surgical 1989 founded ~3,700 colleagues Outcomes leader i
Slide 4: Codman Specialty Surgical
Codman Specialty Surgical Investments focused on higher growth segments, e.g., Advanced Energy, MIS and Neuro Monitoring 4 Neurosurgery 3-5% Market CAGR Market size and growth from third party market reports and internal estimates; 1 TTM revenue as of 9/30/22; Brain Lesion Surgery with MIS Expansion
Slide 5: Tissue Technologies
Tissue Technologies Investments focused on higher growth segments within regenerative technologies market 5 Surgical Reconstruction and Complex Wound Care Private Label MSD growth25-12% Market CAGR1 Complex wounds, burns, traumatic, chronic wounds, nerve and tendon repair Integra® Dermal Matrices •
Slide 6: Integra's Strategic Pillars: Driving an integrated growth strategy
Innovate for outcomes Grow international Broaden care pathway impact Drive operations and customer excellence Cultivate a high- performance culture Growth Drivers Enablers Integra’s Strategic Pillars Driving an integrated growth strategy 6
Slide 7: Innovate for outcomes
2023: Strengthen end-to-end NPI excellence and digital 7 Strengthen customer insight and clinical capabilities Advance digital for analytics value and companion apps CUSA portfolio: extended laparoscopic tip launch; bone tip 510(k) cleared Aurora Evacuator +Coag U.S. launch NeuraGen 3D U.S. launch I
Slide 8: Grow international
2023: Portfolio expansion and local capabilities build-out Grow international 8 Strengthen local leadership: direct sales and marketing, market access, regulatory Accelerate China Tier 2 and Tier 3 Hospital expansion Advance In-China- For-China manufacturing 1 Revenues TTM as of 9/30/22 Launched Neu
Slide 9: Broaden impact on care pathways
2023: Follow the Patient to expand our value to surgeons and systems Broaden impact on care pathways Divested non-core traditional wound care business Completed ACell portfolio integration, expanding wound care solutions Completed strategic M&A gameboard Completed SIA DuraSorb acquisition Appointed
Slide 10: Drive operations and customer excellence
2023 Focus: Strengthen Operations efficiency and quality Drive operations and customer excellence 10 2022 Accomplishments Outsourced and automated global transactional back-office activities Closed high-cost manufacturing facility in France Build responsive and scalable lean processes and organizati
Slide 11: Cultivate a high-performance culture
2023 Focus Advance empowerment and agility Cultivate a high- performance culture 11 2022 Accomplishments Culture of accountability Drive talent development Advance diversity and inclusion Build and execute sustainability roadmap Named to Best Places to Work in NJ Awarded Great Place to Work - Certif
Slide 12: Integra's Strategic Pillars: Strengthening the core while accelerating growth
• Culture of accountability • Diversity & inclusion • Sustainability roadmap Drive operations and customer excellence • Operations and Quality processes • Conversion costs • Global portfolios • Local capabilities • In China, for China • NPI excellence • Clinical studies • Digital innovation Growth D
Slide 13: Driving Sustainability as Enabler of Mission and Strategy
Driving Sustainability as Enabler of Mission and Strategy
Slide 14: Select Preliminary 2022 Results
Select Preliminary 2022 Results 14 Q4 2022 Full-year 2022 Reported Revenue $397M - $398M $1,557M - $1,558M Reported Growth1 ~ -2% ~ 1% Organic Growth1 ~ 3% ~ 4% 1 Growth vs 2021 • Fourth quarter revenues in line with expectations • Resilient markets approaching pre-COVID levels • Overcoming macro he
Slide 15: Long-term Target: Path to higher growth and margin portfolio
Long-term Target Organic Growth Baseline for YoY Delivery 5% – 7% Adj. EPS Growth Double-Digit Adj. Gross Margin 70% – 72% Adj. EBITDA Margin 28% – 30% Adj. FCF Conversion >90% Financial Targets 15 Note: Organic growth, adj. gross margin, adj. EBITDA margin, adj. EPS and adj. FCF conversion are non-
Slide 16: Growth drivers: Diverse portfolio driving 5-7% organic growth
16 Long-term Target Organic Growth Baseline for YoY Delivery 5% – 7% Adj. EPS Growth Double-Digit Adj. Gross Margin 70% – 72% Adj. EBITDA Margin 28% – 30% Adj. FCF Conversion >90% • Executing in our core markets • New Products, e.g.: ‒ CereLink ‒ ACell portfolio • Transforming standards of care: ‒ S
Slide 17: Profitability and cash flow drivers
Long-term Target Organic Growth Baseline for YoY Delivery 5% – 7% Adj. EPS Growth Double-Digit Adj. Gross Margin 70% – 72% Adj. EBITDA Margin 28% – 30% Adj. FCF Conversion >90% • Volume growth • Favorable portfolio mix (NPI and Tissue Technologies contribution) • Price capture through new customers,
Slide 18: Key Takeaways
Capitalizing on strong commercial presence in large, attractive markets with stable growth. Leveraging an extended portfolio of differentiated technologies. Key Takeaways Strong foundation and path to achieve long-term financial targets 18 Strengthening core capabilities to build operational resilie
Slide 19: Appendix: Non-GAAP Reconciliations
Appendix Non-GAAP Reconciliations
Slide 20: Preliminary Fourth Quarter and Full Year 2022 Organic Growth Reconciliation
Preliminary Fourth Quarter and Full Year 2022 Organic Growth Reconciliation 20 (1) Q4 2022 adjustment includes revenues from SIA; FY 2022 adjustment includes revenues from SIA and ACell. (2) Organic revenues have been adjusted to exclude foreign currency, acquisitions and to account for divested and
Integra LifeSciences Holdings — 2023 JP Morgan Healthcare Conference on 6ix